868540-17-4

We have more than 10 years of experience in custom synthesis of compounds. If you are looking for a supplier or manufacturer of Carfilzomib (CAS No.: 868540-17-4) please contact us. We can provide customers with custom synthesis from grams to kilograms and the production of tons of compounds. Now, we also hope to meet your needs for Carfilzomib (CAS No.: 868540-17-4) and other compounds. We can provide high-quality compounds and good service for you.

Send Inquiry

Product Description

Name	Carfilzomib
Synonyms	(2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide;Kyprolis;UNII-72X6E3J5AR;Carfilzomib (PR-171);PR-171
Molecular Formula	C₄₀H₅₇N₅O₇
Molecular Weight	719.91000
CAS Number	868540-17-4
purity	≥99%
Availability	In stock

Application：Carfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) (CAS No.: 868540-17-4) is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.
The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as lenalidomide) and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.
The abbreviation CFZ is common for referring to carfilzomib, but abbreviating drug names is not best practice in medicine.

Hot Tags: